Document Detail


Tumor-volume increase at beginning of primary treatment with topical interferon alpha 2-beta in a case of conjunctiva-cornea intraepithelial neoplasia.
MedLine Citation:
PMID:  17444802     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIMS: The aim of this study was to report on the effectiveness and tumor side effects of topical interferon (INF) alpha 2-beta in a case of conjunctiva-cornea intraepithelial neoplasia (CIN) of a patient that rejected any surgical procedure. METHODS: This study is a case report description. RESULTS: An 81-year-old man with a history of neoplasies of the colon and prostate and anticoagulant treatment was referred for treatment of an ocular surface neoplasia on his left eye. Pathognomonic signs of CIN were present. The patient rejected surgical procedures. A regimen of topical INF alpha 2-beta 4 times daily was administered. An increase in tumor volume of 25% was observable 15 days after the beginning of therapy. No subjective discomfort was reported. The treatment continued with follow-ups every 15 days. The progressive regression was remarkable. Complete regression of the CIN was observable after 60 days of therapy. No other side-effects were detected. CONCLUSIONS: Topical INF alpha 2-beta is a valid choice for the treatment of CIN in patients for whom surgery is not possible. The increase of tumor volume at the beginning of therapy does not require the suspension of treatment.
Authors:
Valentín Huerva; Maria Carmen Sánchez; Irene Mangues
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics     Volume:  23     ISSN:  1080-7683     ISO Abbreviation:  J Ocul Pharmacol Ther     Publication Date:  2007 Apr 
Date Detail:
Created Date:  2007-04-20     Completed Date:  2007-06-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9511091     Medline TA:  J Ocul Pharmacol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  143-5     Citation Subset:  IM    
Affiliation:
Department of Ophthalmology, University Hospital Arnau de Vilanova, Lleida, Spain. vhuerva@mixmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Topical
Aged, 80 and over
Antineoplastic Agents / adverse effects,  therapeutic use*
Carcinoma in Situ / drug therapy*
Conjunctival Neoplasms / drug therapy*
Corneal Diseases / drug therapy*
Eye Neoplasms / drug therapy
Humans
Interferon Alfa-2b / adverse effects,  therapeutic use*
Male
Ophthalmic Solutions
Remission Induction
Tumor Burden / drug effects
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Ophthalmic Solutions; 99210-65-8/Interferon Alfa-2b

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Evaluation of the vascular targeting agent combretastatin a-4 prodrug on retinal neovascularization ...
Next Document:  In vitro diffusion of the immunosuppressant tacrolimus through human and rabbit corneas.